Ирска - Енглески - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - sodium chloride; potassium chloride; calcium chloride dihydrate; sodium lactate solution 50% - solution for infusion - %v/v - solutions affecting the electrolyte balance; electrolytes

Ирска - Енглески - HPRA (Health Products Regulatory Authority)

b. braun medical limited - sodium chloride; potassium chloride; sodium lactate solution; calcium chloride dihydrate - solution for infusion - 6/6.24/0.40/0.27 %v/v - solutions affecting the electrolyte balance; electrolytes

Сједињене Америчке Државе - Енглески - NLM (National Library of Medicine)

sanofi-aventis u.s. llc - insulin glargine (unii: 2zm8cx04rz) (insulin glargine - unii:2zm8cx04rz), lixisenatide (unii: 74o62bb01u) (lixisenatide - unii:74o62bb01u) - insulin glargine 100 u in 1 ml - soliqua 100/33 is a combination of insulin glargine and lixisenatide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use : - soliqua 100/33 has not been studied in patients with a history of pancreatitis [see warnings and precautions (5.2)] . consider other antidiabetic therapies in patients with a history of pancreatitis. - soliqua 100/33 is not recommended for use in combination with any other product containing a glp-1 receptor agonist [see warnings and precautions (5.5)] . - soliqua 100/33 is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. - soliqua 100/33 has not been studied in patients with gastroparesis and is not recommended in patients with gastroparesis. - soliqua 100/33 has not been studied in combination with prandial insulin. soliqua 100/33 is contraindicated: - during episodes of hypoglycemia [see warnings and precautions (5.6)] . - in patients w

Малта - Енглески - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - powder and solvent for concentrate for solution for infusion - carmustine 100 mg - antineoplastic agents

Ирска - Енглески - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - carmustine - powder and solvent for concentrate for solution for infusion - carmustine

Ирска - Енглески - HPRA (Health Products Regulatory Authority)

tillomed pharma gmbh - carmustine - powder and solvent for concentrate for solution for infusion - 100 milligram(s) - nitrosoureas; carmustine

Ирска - Енглески - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - carmustine - powder and solvent for concentrate for solution for infusion - carmustine

Ирска - Енглески - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - carmustine - powder and solvent for concentrate for solution for infusion - carmustine

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

vantive pty ltd - glucose monohydrate, quantity: 42.5 g/l (equivalent: glucose, qty 38.6 g/l); sodium chloride, quantity: 5.38 g/l; magnesium chloride hexahydrate, quantity: 51 mg/l; calcium chloride dihydrate, quantity: 0.184 g/l; sodium bicarbonate, quantity: 2.1 g/l; sodium lactate, quantity: 1.68 g/l - solution, dialysis - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - physioneal 40 is indicated for use in peritoneal dialysis in patients with acute or chronic renal failure.

Аустралија - Енглески - Department of Health (Therapeutic Goods Administration)

vantive pty ltd - sodium bicarbonate, quantity: 2.1 g/l; sodium lactate, quantity: 1.68 g/l; magnesium chloride hexahydrate, quantity: 51 mg/l; glucose monohydrate, quantity: 25 g/l (equivalent: glucose, qty 22.7 g/l); calcium chloride dihydrate, quantity: 0.184 g/l; sodium chloride, quantity: 5.38 g/l - solution, dialysis - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - physioneal 40 is indicated for use in peritoneal dialysis in patients with acute or chronic renal failure.